This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v2.0 was used to generate the results found in this report.
-
Working with individual set: KIRP-TP
-
Number of patients in set: 112
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:KIRP-TP.final_analysis_set.maf
-
Significantly mutated genes (q ≤ 0.1): 18
-
Mutations seen in COSMIC: 43
-
Significantly mutated genes in COSMIC territory: 11
-
Genes with clustered mutations (≤ 3 aa apart): 72
-
Significantly mutated genesets: 0
-
Significantly mutated genesets: (excluding sig. mutated genes):0
-
Read 112 MAFs of type "Broad"
-
Total number of mutations in input MAFs: 10029
-
After removing 78 mutations outside chr1-24: 9951
-
After removing 285 noncoding mutations: 9666
-
After collapsing adjacent/redundant mutations: 8213
-
Number of mutations before filtering: 8213
-
After removing 413 mutations outside gene set: 7800
-
After removing 9 mutations outside category set: 7791
-
After removing 2 "impossible" mutations in
-
gene-patient-category bins of zero coverage: 7367
type | count |
---|---|
Frame_Shift_Del | 511 |
Frame_Shift_Ins | 199 |
In_Frame_Del | 166 |
In_Frame_Ins | 38 |
Missense_Mutation | 4569 |
Nonsense_Mutation | 248 |
Nonstop_Mutation | 7 |
Silent | 1705 |
Splice_Site | 345 |
Translation_Start_Site | 3 |
Total | 7791 |
category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio |
---|---|---|---|---|---|---|
*CpG->T | 477 | 186386483 | 2.6e-06 | 2.6 | 1.4 | 2.1 |
*Cp(A/C/T)->T | 863 | 1509673770 | 5.7e-07 | 0.57 | 0.31 | 1.7 |
A->G | 861 | 1622585631 | 5.3e-07 | 0.53 | 0.29 | 2.3 |
transver | 2368 | 3318645884 | 7.1e-07 | 0.71 | 0.39 | 5 |
indel+null | 1506 | 3318645884 | 4.5e-07 | 0.45 | 0.25 | NaN |
double_null | 9 | 3318645884 | 2.7e-09 | 0.0027 | 0.0015 | NaN |
Total | 6084 | 3318645884 | 1.8e-06 | 1.8 | 1 | 3.5 |
The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom).
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Column Descriptions:
-
N = number of sequenced bases in this gene across the individual set
-
n = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
n1 = number of nonsilent mutations of type: *CpG->T
-
n2 = number of nonsilent mutations of type: *Cp(A/C/T)->T
-
n3 = number of nonsilent mutations of type: A->G
-
n4 = number of nonsilent mutations of type: transver
-
n5 = number of nonsilent mutations of type: indel+null
-
n6 = number of nonsilent mutations of type: double_null
-
p_classic = p-value for the observed amount of nonsilent mutations being elevated in this gene
-
p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene
-
p_cons = p-value for enrichment of mutations at evolutionarily most-conserved sites in gene
-
p_joint = p-value for clustering + conservation
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_classic | p_ns_s | p_clust | p_cons | p_joint | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | CDC27 | cell division cycle 27 homolog (S. cerevisiae) | 280332 | 4 | 4 | 1 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0.00082 | 1 | 6e-07 | 0.078 | 0 | <1.00e-15 | <9.06e-12 |
2 | KCNK5 | potassium channel, subfamily K, member 5 | 159653 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0.0075 | 0.33 | 0.26 | 0 | 0 | <1.00e-15 | <9.06e-12 |
3 | PLAC4 | placenta-specific 4 | 20310 | 5 | 4 | 4 | 0 | 0 | 0 | 1 | 0 | 4 | 0 | 1.2e-09 | 0.74 | 0.52 | 0.0016 | 0.0044 | 1.37e-10 | 6.24e-07 |
4 | MET | met proto-oncogene (hepatocyte growth factor receptor) | 478818 | 9 | 9 | 8 | 0 | 0 | 3 | 2 | 4 | 0 | 0 | 7.7e-08 | 0.065 | 0.00038 | 0.0011 | 0.000066 | 1.38e-10 | 6.24e-07 |
5 | MUC4 | mucin 4, cell surface associated | 365020 | 12 | 11 | 9 | 1 | 1 | 2 | 2 | 7 | 0 | 0 | 3e-10 | 0.12 | NaN | NaN | NaN | 3.04e-10 | 1.10e-06 |
6 | IL32 | interleukin 32 | 62375 | 4 | 4 | 2 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 3.8e-06 | 1 | 0.000021 | 0.9 | 0.0002 | 1.71e-08 | 5.17e-05 |
7 | NF2 | neurofibromin 2 (merlin) | 181882 | 7 | 7 | 7 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 2.4e-08 | 0.43 | 0.43 | 0.98 | 0.59 | 2.73e-07 | 0.000707 |
8 | NBPF1 | neuroblastoma breakpoint family, member 1 | 371646 | 8 | 7 | 2 | 0 | 0 | 1 | 0 | 0 | 7 | 0 | 1.3e-06 | 0.021 | NaN | NaN | NaN | 1.30e-06 | 0.00294 |
9 | PPARGC1B | peroxisome proliferator-activated receptor gamma, coactivator 1 beta | 320747 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0.02 | 1 | 0.000092 | 0.00038 | 7.4e-06 | 2.45e-06 | 0.00494 |
10 | FOXE1 | forkhead box E1 (thyroid transcription factor 2) | 51983 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0.000045 | 1 | 0.00035 | 0.61 | 0.0049 | 3.60e-06 | 0.00653 |
11 | KRTAP4-11 | keratin associated protein 4-11 | 60031 | 4 | 4 | 3 | 1 | 0 | 0 | 2 | 2 | 0 | 0 | 3.3e-07 | 0.83 | 0.36 | 0.85 | 0.77 | 4.14e-06 | 0.00682 |
12 | LGI4 | leucine-rich repeat LGI family, member 4 | 78713 | 4 | 4 | 4 | 0 | 0 | 1 | 1 | 2 | 0 | 0 | 7.2e-06 | 0.28 | 0.35 | 0.015 | 0.046 | 5.22e-06 | 0.00789 |
13 | NUDT11 | nudix (nucleoside diphosphate linked moiety X)-type motif 11 | 47767 | 3 | 3 | 2 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0.000037 | 0.61 | 0.0069 | 0.88 | 0.022 | 1.20e-05 | 0.0167 |
14 | HRCT1 | histidine rich carboxyl terminus 1 | 34801 | 3 | 3 | 2 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0.000023 | 0.6 | 0.019 | 0.96 | 0.068 | 2.25e-05 | 0.0278 |
15 | STAG3L2 | stromal antigen 3-like 2 | 30982 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0.000023 | 1 | NaN | NaN | NaN | 2.30e-05 | 0.0278 |
16 | UBXN11 | UBX domain protein 11 | 169165 | 4 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 4 | 0 | 0.0029 | 1 | 0.00029 | 0.2 | 0.00075 | 3.03e-05 | 0.0343 |
17 | BHMT | betaine-homocysteine methyltransferase | 139714 | 4 | 4 | 4 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0.000026 | 0.31 | 0.28 | 0.11 | 0.22 | 7.42e-05 | 0.0791 |
18 | PCDHGC5 | protocadherin gamma subfamily C, 5 | 324524 | 15 | 13 | 15 | 6 | 0 | 3 | 4 | 3 | 4 | 1 | 0.000078 | 0.67 | NaN | NaN | NaN | 7.85e-05 | 0.0791 |
19 | ACSBG2 | acyl-CoA synthetase bubblegum family member 2 | 226349 | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0.0077 | 0.61 | 0.000081 | 1 | 0.0011 | 0.000110 | 0.105 |
20 | PARD6B | par-6 partitioning defective 6 homolog beta (C. elegans) | 118830 | 4 | 4 | 4 | 0 | 0 | 0 | 2 | 0 | 2 | 0 | 0.000016 | 0.26 | 0.63 | 0.71 | 0.91 | 0.000181 | 0.164 |
21 | ATP1B1 | ATPase, Na+/K+ transporting, beta 1 polypeptide | 104177 | 4 | 4 | 4 | 0 | 0 | 0 | 1 | 1 | 2 | 0 | 0.000032 | 0.61 | 0.93 | 0.22 | 0.56 | 0.000212 | 0.183 |
22 | NFE2L2 | nuclear factor (erythroid-derived 2)-like 2 | 199571 | 3 | 3 | 3 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0.0039 | 0.46 | 0.024 | 0.011 | 0.005 | 0.000229 | 0.189 |
23 | OR2T35 | olfactory receptor, family 2, subfamily T, member 35 | 33964 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0.000065 | 1 | 0.015 | 0.92 | 0.45 | 0.000336 | 0.265 |
24 | FAT1 | FAT tumor suppressor homolog 1 (Drosophila) | 1538743 | 8 | 8 | 8 | 1 | 1 | 0 | 2 | 2 | 3 | 0 | 0.006 | 0.5 | 0.003 | 0.48 | 0.0057 | 0.000388 | 0.290 |
25 | SAV1 | salvador homolog 1 (Drosophila) | 129761 | 3 | 3 | 3 | 0 | 0 | 1 | 0 | 0 | 2 | 0 | 0.0002 | 0.74 | 0.1 | 0.97 | 0.18 | 0.000400 | 0.290 |
26 | COCH | coagulation factor C homolog, cochlin (Limulus polyphemus) | 186274 | 4 | 4 | 4 | 0 | 1 | 0 | 1 | 2 | 0 | 0 | 9e-05 | 0.31 | 0.7 | 0.18 | 0.58 | 0.000570 | 0.393 |
27 | POMC | proopiomelanocortin (adrenocorticotropin/ beta-lipotropin/ alpha-melanocyte stimulating hormone/ beta-melanocyte stimulating hormone/ beta-endorphin) | 64181 | 3 | 3 | 3 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0.00015 | 0.52 | 0.3 | 0.5 | 0.38 | 0.000620 | 0.393 |
28 | POTEC | POTE ankyrin domain family, member C | 167445 | 3 | 3 | 3 | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0.00024 | 0.35 | 0.12 | 0.38 | 0.24 | 0.000620 | 0.393 |
29 | EPSTI1 | epithelial stromal interaction 1 (breast) | 143344 | 3 | 2 | 3 | 0 | 0 | 1 | 0 | 2 | 0 | 0 | 0.0074 | 0.48 | 0.0017 | 0.38 | 0.0079 | 0.000629 | 0.393 |
30 | SETD2 | SET domain containing 2 | 712734 | 7 | 7 | 7 | 0 | 0 | 0 | 0 | 2 | 5 | 0 | 0.00018 | 0.38 | 0.36 | 0.26 | 0.34 | 0.000654 | 0.395 |
31 | CD86 | CD86 molecule | 113374 | 3 | 3 | 3 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0.00018 | 0.6 | 0.31 | 0.093 | 0.38 | 0.000719 | 0.406 |
32 | CUL3 | cullin 3 | 261328 | 5 | 4 | 5 | 1 | 0 | 1 | 1 | 1 | 2 | 0 | 0.00073 | 0.59 | 0.072 | 0.6 | 0.097 | 0.000750 | 0.406 |
33 | EBF2 | early B-cell factor 2 | 193894 | 3 | 3 | 3 | 1 | 0 | 0 | 0 | 3 | 0 | 0 | 0.0057 | 0.8 | 0.0069 | 0.23 | 0.013 | 0.000757 | 0.406 |
34 | OR8I2 | olfactory receptor, family 8, subfamily I, member 2 | 103742 | 3 | 3 | 3 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0.00031 | 0.49 | 0.27 | 0.17 | 0.23 | 0.000762 | 0.406 |
35 | EEF1B2 | eukaryotic translation elongation factor 1 beta 2 | 78624 | 2 | 2 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0.0013 | 0.42 | 0.013 | 1 | 0.059 | 0.000794 | 0.411 |
In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.
rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q |
---|---|---|---|---|---|---|---|---|---|
1 | MET | met proto-oncogene (hepatocyte growth factor receptor) | 9 | 34 | 4 | 3808 | 12 | 9.8e-11 | 4.4e-07 |
2 | FGFR3 | fibroblast growth factor receptor 3 (achondroplasia, thanatophoric dwarfism) | 5 | 62 | 3 | 6944 | 1469 | 3.4e-07 | 0.00077 |
3 | NF2 | neurofibromin 2 (merlin) | 7 | 550 | 4 | 61600 | 29 | 6.2e-06 | 0.0093 |
4 | SMARCA4 | SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 4 | 5 | 30 | 2 | 3360 | 3 | 0.000019 | 0.021 |
5 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 2 | 52 | 2 | 5824 | 29208 | 0.000057 | 0.051 |
6 | BRAF | v-raf murine sarcoma viral oncogene homolog B1 | 2 | 89 | 2 | 9968 | 14380 | 0.00016 | 0.084 |
7 | CDCA8 | cell division cycle associated 8 | 1 | 1 | 1 | 112 | 1 | 0.00021 | 0.084 |
8 | FLCN | folliculin | 1 | 1 | 1 | 112 | 1 | 0.00021 | 0.084 |
9 | G6PC | glucose-6-phosphatase, catalytic subunit | 1 | 1 | 1 | 112 | 1 | 0.00021 | 0.084 |
10 | PLXDC2 | plexin domain containing 2 | 1 | 1 | 1 | 112 | 1 | 0.00021 | 0.084 |
Note:
n - number of (nonsilent) mutations in this gene across the individual set.
cos = number of unique mutated sites in this gene in COSMIC
n_cos = overlap between n and cos.
N_cos = number of individuals times cos.
cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.
p = p-value for seeing the observed amount of overlap in this gene)
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
num | gene | desc | n | mindist | nmuts0 | nmuts3 | nmuts12 | npairs0 | npairs3 | npairs12 |
---|---|---|---|---|---|---|---|---|---|---|
2368 | MUC4 | mucin 4, cell surface associated | 12 | 0 | 6 | 6 | 15 | 6 | 6 | 15 |
54 | ACSBG2 | acyl-CoA synthetase bubblegum family member 2 | 3 | 0 | 3 | 3 | 3 | 3 | 3 | 3 |
4435 | ZNF814 | zinc finger protein 814 | 6 | 0 | 3 | 3 | 3 | 3 | 3 | 3 |
2259 | MET | met proto-oncogene (hepatocyte growth factor receptor) | 9 | 0 | 1 | 3 | 4 | 1 | 3 | 4 |
2745 | PCF11 | PCF11, cleavage and polyadenylation factor subunit, homolog (S. cerevisiae) | 8 | 0 | 1 | 2 | 10 | 1 | 2 | 10 |
1219 | EP400 | E1A binding protein p400 | 6 | 0 | 1 | 2 | 2 | 1 | 2 | 2 |
1239 | EPSTI1 | epithelial stromal interaction 1 (breast) | 3 | 0 | 1 | 1 | 3 | 1 | 1 | 3 |
2032 | KRTAP4-9 | keratin associated protein 4-9 | 3 | 0 | 1 | 1 | 3 | 1 | 1 | 3 |
92 | ADAMTS7 | ADAM metallopeptidase with thrombospondin type 1 motif, 7 | 3 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
199 | ANAPC5 | anaphase promoting complex subunit 5 | 3 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
Note:
n - number of mutations in this gene in the individual set.
mindist - distance (in aa) between closest pair of mutations in this gene
npairs3 - how many pairs of mutations are within 3 aa of each other.
npairs12 - how many pairs of mutations are within 12 aa of each other.
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | MTORPATHWAY | Mammalian target of rapamycin (mTOR) senses mitogenic factors and nutrients, including ATP, and induces cell proliferation. | AKT1, EIF3S10, EIF4A1, EIF4A2, EIF4B, EIF4E, EIF4EBP1, EIF4G1, EIF4G2, EIF4G3, FKBP1A, FRAP1, MKNK1, PDK2, PDPK1, PIK3CA, PIK3R1, PPP2CA, PTEN, RPS6, RPS6KB1, TSC1, TSC2 | 21 | EIF4A1(1), EIF4B(2), EIF4G1(2), EIF4G3(5), PIK3CA(2), PIK3R1(1), PTEN(2), TSC1(2), TSC2(4) | 4653778 | 21 | 18 | 21 | 2 | 2 | 6 | 3 | 4 | 6 | 0 | 0.056 | 0.001 | 0.61 |
2 | KREBPATHWAY | The Krebs (citric acid) cycle takes place in mitochondria, where it extracts energy in the form of electron carriers NADH and FADH2, which drive the electron transport chain. | ACO2, CS, FH, IDH2, MDH1, OGDH, SDHA, SUCLA2 | 8 | FH(1), IDH2(1), MDH1(1), OGDH(2), SDHA(3) | 1572837 | 8 | 8 | 8 | 0 | 0 | 3 | 1 | 1 | 3 | 0 | 0.052 | 0.0025 | 0.62 |
3 | ALANINE_AND_ASPARTATE_METABOLISM | AARS, ABAT, ADSL, ADSS, AGXT, AGXT2, ASL, ASNS, ASPA, ASS, CAD, CRAT, DARS, DDO, GAD1, GAD2, GOT1, GOT2, GPT, GPT2, NARS, PC | 21 | AARS(1), ADSL(1), AGXT(1), AGXT2(1), ASNS(1), CAD(3), CRAT(1), DARS(3), DDO(1), GPT(2), PC(4) | 4376807 | 19 | 17 | 19 | 1 | 0 | 3 | 1 | 8 | 7 | 0 | 0.078 | 0.003 | 0.62 | |
4 | CBLPATHWAY | Activated EGF receptors undergo endocytosis into clathrin-coated vesicles, where they are recycled to the membrane or ubiquitinated by Cbl. | CBL, CSF1R, EGF, EGFR, GRB2, MET, PDGFRA, PRKCA, PRKCB1, SH3GLB1, SH3GLB2, SH3KBP1, SRC | 12 | CSF1R(1), EGF(1), MET(9), PDGFRA(2) | 3254544 | 13 | 12 | 12 | 1 | 1 | 3 | 2 | 6 | 1 | 0 | 0.11 | 0.0063 | 0.96 |
5 | CITRATE_CYCLE_TCA_CYCLE | ACO1, ACO2, CS, DLD, DLST, DLSTP, FH, IDH1, IDH2, IDH3A, IDH3B, IDH3G, MDH1, MDH2, PC, PCK1, SDHA, SDHA, SDHAL2, SDHB, SUCLA2, SUCLG1, SUCLG2 | 20 | ACO1(1), DLD(1), FH(1), IDH2(1), MDH1(1), PC(4), PCK1(1), SDHA(3) | 3444763 | 13 | 12 | 13 | 0 | 0 | 2 | 2 | 3 | 6 | 0 | 0.035 | 0.013 | 1 | |
6 | DNAFRAGMENTPATHWAY | DNA fragmentation during apoptosis is effected by DFF, a caspase-activated DNAse, and by endonuclease G. | CASP3, CASP7, DFFA, DFFB, ENDOG, GZMB, HMGB1, HMGB2, TOP2A, TOP2B | 9 | HMGB1(3), HMGB2(2), TOP2B(3) | 1518294 | 8 | 7 | 8 | 0 | 1 | 1 | 1 | 3 | 2 | 0 | 0.21 | 0.016 | 1 |
7 | HSA00830_RETINOL_METABOLISM | Genes involved in retinol metabolism | ALDH1A1, ALDH1A2, BCMO1, RDH5 | 4 | BCMO1(2), RDH5(2) | 649405 | 4 | 4 | 4 | 1 | 0 | 0 | 3 | 0 | 1 | 0 | 0.72 | 0.018 | 1 |
8 | HSA00252_ALANINE_AND_ASPARTATE_METABOLISM | Genes involved in alanine and aspartate metabolism | AARS, AARS2, ABAT, ACY3, ADSL, ADSS, ADSSL1, AGXT, AGXT2, ASL, ASNS, ASPA, ASRGL1, ASS1, CAD, CRAT, DARS, DARS2, DDO, DLAT, DLD, GAD1, GAD2, GOT1, GOT2, GPT, GPT2, NARS, NARS2, PC, PDHA1, PDHA2, PDHB | 33 | AARS(1), AARS2(1), ACY3(1), ADSL(1), AGXT(1), AGXT2(1), ASNS(1), CAD(3), CRAT(1), DARS(3), DDO(1), DLD(1), GPT(2), PC(4) | 6354267 | 22 | 19 | 22 | 1 | 0 | 3 | 2 | 9 | 8 | 0 | 0.039 | 0.019 | 1 |
9 | RABPATHWAY | Rab family GTPases regulate vesicle transport, endocytosis and exocytosis, and vesicle docking via interactions with the rabphilins. | ACTA1, MEL, RAB11A, RAB1A, RAB2, RAB27A, RAB3A, RAB4A, RAB5A, RAB6A, RAB7, RAB9A | 9 | ACTA1(1), RAB11A(1), RAB3A(1), RAB6A(1) | 711732 | 4 | 4 | 4 | 1 | 0 | 1 | 0 | 2 | 1 | 0 | 0.81 | 0.022 | 1 |
10 | HSA01040_POLYUNSATURATED_FATTY_ACID_BIOSYNTHESIS | Genes involved in polyunsaturated fatty acid biosynthesis | ACAA1, ACOX1, ACOX3, ELOVL2, ELOVL5, ELOVL6, FADS1, FADS2, FASN, GPSN2, HADHA, HSD17B12, PECR, SCD | 13 | ACAA1(3), ACOX1(1), ACOX3(2), ELOVL6(1), FADS1(1), FASN(3), HADHA(1) | 2460627 | 12 | 9 | 12 | 1 | 1 | 4 | 0 | 6 | 1 | 0 | 0.096 | 0.022 | 1 |
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | MTORPATHWAY | Mammalian target of rapamycin (mTOR) senses mitogenic factors and nutrients, including ATP, and induces cell proliferation. | AKT1, EIF3S10, EIF4A1, EIF4A2, EIF4B, EIF4E, EIF4EBP1, EIF4G1, EIF4G2, EIF4G3, FKBP1A, FRAP1, MKNK1, PDK2, PDPK1, PIK3CA, PIK3R1, PPP2CA, PTEN, RPS6, RPS6KB1, TSC1, TSC2 | 21 | EIF4A1(1), EIF4B(2), EIF4G1(2), EIF4G3(5), PIK3CA(2), PIK3R1(1), PTEN(2), TSC1(2), TSC2(4) | 4653778 | 21 | 18 | 21 | 2 | 2 | 6 | 3 | 4 | 6 | 0 | 0.056 | 0.001 | 0.61 |
2 | KREBPATHWAY | The Krebs (citric acid) cycle takes place in mitochondria, where it extracts energy in the form of electron carriers NADH and FADH2, which drive the electron transport chain. | ACO2, CS, FH, IDH2, MDH1, OGDH, SDHA, SUCLA2 | 8 | FH(1), IDH2(1), MDH1(1), OGDH(2), SDHA(3) | 1572837 | 8 | 8 | 8 | 0 | 0 | 3 | 1 | 1 | 3 | 0 | 0.052 | 0.0025 | 0.62 |
3 | ALANINE_AND_ASPARTATE_METABOLISM | AARS, ABAT, ADSL, ADSS, AGXT, AGXT2, ASL, ASNS, ASPA, ASS, CAD, CRAT, DARS, DDO, GAD1, GAD2, GOT1, GOT2, GPT, GPT2, NARS, PC | 21 | AARS(1), ADSL(1), AGXT(1), AGXT2(1), ASNS(1), CAD(3), CRAT(1), DARS(3), DDO(1), GPT(2), PC(4) | 4376807 | 19 | 17 | 19 | 1 | 0 | 3 | 1 | 8 | 7 | 0 | 0.078 | 0.003 | 0.62 | |
4 | CITRATE_CYCLE_TCA_CYCLE | ACO1, ACO2, CS, DLD, DLST, DLSTP, FH, IDH1, IDH2, IDH3A, IDH3B, IDH3G, MDH1, MDH2, PC, PCK1, SDHA, SDHA, SDHAL2, SDHB, SUCLA2, SUCLG1, SUCLG2 | 20 | ACO1(1), DLD(1), FH(1), IDH2(1), MDH1(1), PC(4), PCK1(1), SDHA(3) | 3444763 | 13 | 12 | 13 | 0 | 0 | 2 | 2 | 3 | 6 | 0 | 0.035 | 0.013 | 1 | |
5 | DNAFRAGMENTPATHWAY | DNA fragmentation during apoptosis is effected by DFF, a caspase-activated DNAse, and by endonuclease G. | CASP3, CASP7, DFFA, DFFB, ENDOG, GZMB, HMGB1, HMGB2, TOP2A, TOP2B | 9 | HMGB1(3), HMGB2(2), TOP2B(3) | 1518294 | 8 | 7 | 8 | 0 | 1 | 1 | 1 | 3 | 2 | 0 | 0.21 | 0.016 | 1 |
6 | HSA00830_RETINOL_METABOLISM | Genes involved in retinol metabolism | ALDH1A1, ALDH1A2, BCMO1, RDH5 | 4 | BCMO1(2), RDH5(2) | 649405 | 4 | 4 | 4 | 1 | 0 | 0 | 3 | 0 | 1 | 0 | 0.72 | 0.018 | 1 |
7 | HSA00252_ALANINE_AND_ASPARTATE_METABOLISM | Genes involved in alanine and aspartate metabolism | AARS, AARS2, ABAT, ACY3, ADSL, ADSS, ADSSL1, AGXT, AGXT2, ASL, ASNS, ASPA, ASRGL1, ASS1, CAD, CRAT, DARS, DARS2, DDO, DLAT, DLD, GAD1, GAD2, GOT1, GOT2, GPT, GPT2, NARS, NARS2, PC, PDHA1, PDHA2, PDHB | 33 | AARS(1), AARS2(1), ACY3(1), ADSL(1), AGXT(1), AGXT2(1), ASNS(1), CAD(3), CRAT(1), DARS(3), DDO(1), DLD(1), GPT(2), PC(4) | 6354267 | 22 | 19 | 22 | 1 | 0 | 3 | 2 | 9 | 8 | 0 | 0.039 | 0.019 | 1 |
8 | RABPATHWAY | Rab family GTPases regulate vesicle transport, endocytosis and exocytosis, and vesicle docking via interactions with the rabphilins. | ACTA1, MEL, RAB11A, RAB1A, RAB2, RAB27A, RAB3A, RAB4A, RAB5A, RAB6A, RAB7, RAB9A | 9 | ACTA1(1), RAB11A(1), RAB3A(1), RAB6A(1) | 711732 | 4 | 4 | 4 | 1 | 0 | 1 | 0 | 2 | 1 | 0 | 0.81 | 0.022 | 1 |
9 | HSA01040_POLYUNSATURATED_FATTY_ACID_BIOSYNTHESIS | Genes involved in polyunsaturated fatty acid biosynthesis | ACAA1, ACOX1, ACOX3, ELOVL2, ELOVL5, ELOVL6, FADS1, FADS2, FASN, GPSN2, HADHA, HSD17B12, PECR, SCD | 13 | ACAA1(3), ACOX1(1), ACOX3(2), ELOVL6(1), FADS1(1), FASN(3), HADHA(1) | 2460627 | 12 | 9 | 12 | 1 | 1 | 4 | 0 | 6 | 1 | 0 | 0.096 | 0.022 | 1 |
10 | UBIQUINONE_BIOSYNTHESIS | NDUFA1, NDUFA10, NDUFA11, NDUFA4, NDUFA5, NDUFA8, NDUFB2, NDUFB4, NDUFB5, NDUFB6, NDUFB7, NDUFS1, NDUFS2, NDUFV1, NDUFV2 | 15 | NDUFA10(1), NDUFB2(1), NDUFB5(1), NDUFS1(2), NDUFV1(1) | 1169848 | 6 | 6 | 6 | 0 | 0 | 1 | 0 | 3 | 2 | 0 | 0.32 | 0.023 | 1 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.